Nurix Therapeutics annual operating margin
2019
2020
2021
2022
2023
2024
2025
Nurix Therapeutics's operating margin was −340.16% for fiscal 2025.
View full Nurix Therapeutics company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-11-30 | −340.16% | +50.36 pp |
| 2024 | 2024-11-30 | −390.52% | −189.11 pp |
| 2023 | 2023-11-30 | −201.41% | +274.59 pp |
| 2022 | 2022-11-30 | −476.01% | −79.75 pp |
| 2021 | 2021-11-30 | −396.26% | −31.59 pp |
| 2020 | 2020-11-30 | −364.66% | −293.20 pp |
| 2019 | 2019-11-30 | −71.46% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-05-31 | −1,041.73% | −932.05 pp |
| Q1 2026 | 2026-02-28 | −1,479.45% | −1138.78 pp |
| Q4 2025 | 2025-11-30 | −612.03% | −125.30 pp |
| Q3 2025 | 2025-08-31 | −1,157.65% | −723.82 pp |
| Q2 2025 | 2025-05-31 | −109.68% | +291.74 pp |
| Q1 2025 | 2025-02-28 | −340.67% | −68.02 pp |
| Q4 2024 | 2024-11-30 | −486.73% | −187.67 pp |
| Q3 2024 | 2024-08-31 | −433.83% | −217.17 pp |
| Q2 2024 | 2024-05-31 | −401.42% | −314.17 pp |
| Q1 2024 | 2024-02-29 | −272.65% | +65.95 pp |
| Q4 2023 | 2023-11-30 | −299.06% | +418.77 pp |
| Q3 2023 | 2023-08-31 | −216.67% | +216.27 pp |
| Q2 2023 | 2023-05-31 | −87.25% | +312.64 pp |
| Q1 2023 | 2023-02-28 | −338.60% | +105.67 pp |
| Q4 2022 | 2022-11-30 | −717.82% | −204.67 pp |
| Q3 2022 | 2022-08-31 | −432.93% | −150.09 pp |
| Q2 2022 | 2022-05-31 | −399.89% | −27.39 pp |
| Q1 2022 | 2022-02-28 | −444.28% | +45.09 pp |
| Q4 2021 | 2021-11-30 | −513.16% | −214.04 pp |
| Q3 2021 | 2021-08-31 | −282.84% | +186.97 pp |
| Q2 2021 | 2021-05-31 | −372.50% | −56.14 pp |
| Q1 2021 | 2021-02-28 | −489.36% | −51.06 pp |
| Q4 2020 | 2020-11-30 | −299.12% | — |
| Q3 2020 | 2020-08-31 | −469.82% | — |
| Q2 2020 | 2020-05-31 | −316.36% | — |
| Q1 2020 | 2020-02-29 | −438.30% | — |
Over the last five reported fiscal years, Nurix Therapeutics's operating margin increased from −364.66% to −340.16%, a change of +24.50 percentage points. The latest reported quarter, Q2 2026, shows −1,041.73%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nurix Therapeutics filings at SEC.gov ↗